- 专利标题： T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE
-
申请号： US16144226申请日： 2018-09-27
-
公开(公告)号： US20190016777A1公开(公告)日： 2019-01-17
- 发明人: Paul F. Robbins , Steven A. Rosenberg , Shiqui Zhu , Steven A. Feldman , Richard A. Morgan
- 申请人： Paul F. Robbins , Steven A. Rosenberg , Shiqui Zhu , Steven A. Feldman , Richard A. Morgan
- 申请人地址： US MD Bethesda
- 专利权人： The United States of America,as represented by the Secretary,Department of Health and Human Services
- 当前专利权人： The United States of America,as represented by the Secretary,Department of Health and Human Services
- 当前专利权人地址： US MD Bethesda
- 主分类号： C07K14/705
- IPC分类号： C07K14/705 ; C07K14/725 ; C07K16/28 ; G01N33/574 ; A61K39/00
摘要：
The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
公开/授权文献
信息查询
